Treatment

VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor) clinical trials

4 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, controlled, safety and tolerability study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with thyroid eye disease (TED)
This study is testing a new medicine, VRDN-001, for people with thyroid eye disease. It’s looking at how safe the medicine is and if it causes any side effects over 15 weeks.
For: Thyroid eye disease
Germany · Netherlands · Poland
Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal studies
This study is for people with Thyroid Eye Disease whose previous treatment didn't work completely. It's testing a new medicine (VRDN-001) to see if it can reduce bulging eyes and improve other symptoms, aiming to find better ways to help those still struggling.
For: Thyroid eye disease
Czechia · Italy · Spain
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-masked, placebo-controlled safety, tolerability, and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with chronic thyroid eye disease (TED)
This study is testing a new medicine, VRDN-001, for people with an eye condition called Thyroid Eye Disease (TED). Researchers want to see if it's safe, if it helps improve eye bulging and other symptoms, and how well people tolerate it.
For: Thyroid eye disease
Spain · Hungary · Poland
Ongoing, recruitingPhase II and Phase III (Integrated)
A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)
This study is testing a new medicine, VRDN-001, for Thyroid Eye Disease (TED). It looks at how safe the medicine is, how well people tolerate it, and if it helps reduce eye bulging (proptosis) and other symptoms caused by TED. The study includes healthy volunteers and people with TED.
For: Thyroid eye disease (TED)
Spain · Germany · France

A randomized, controlled, safety and tolerability study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with thyroid eye disease (TED)

An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal studies

A randomized, double-masked, placebo-controlled safety, tolerability, and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with chronic thyroid eye disease (TED)

A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)